Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. URGN.NASDAQ

UroGen Pharma Ltd (URGN NASDAQ) stock market data APIs

$16.62 0.27(1.7%) as of July 26, 2024
Price chart is built with Anychart

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Ltd Financial Data Overview

16.35
16.62
-
16.7785
15.99
10.6001-24.13
672 M
41 170 K
84 302 K
-0.97
1.123
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'URGN',
Type: 'Common Stock',
Name: 'UroGen Pharma Ltd',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00GFCC613',
ISIN: 'IL0011407140',
CUSIP: 'M96088105',
CIK: '1668243',
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2017-05-04',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

UroGen Pharma Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 84 302 K
  • EBITDA -68 523 000
  • Earnings Per Share -3.22
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get UroGen Pharma Ltd Earnings via APIs

  • Latest Release 2024-05-13
  • EPS/Forecast -0.87

Get UroGen Pharma Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get UroGen Pharma Ltd latest news via APIs

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET PRINCETON, N.J., August 02, 2023--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to...

‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks

It’s been clear for a while now that the stock market is on an upward trajectory, buoyed by a resilient economy and retreating high inflation. The good news, according to John Stoltzfus, Chief Inves...
Do you have any questions?
support@eodhistoricaldata.com